findmyKOL
Clinical trialNCT06519110Not, yet, recruitingPhase 2Interventional

Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations

SponsorConvalife (Shanghai) Co., Ltd.Enrollment60Advanced Solid Tumor
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • jin Li, ph.D

    Shanghai GoBroad Cancer Hospital China Pharmaceutical University

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
10 Aug 2024
Primary completion
14 Feb 2026
Completion
15 Apr 2026
Last update posted
25 Jul 2024
Registered enrollment
60
Registry id
NCT06519110

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.